Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | GSK3368715 |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK3368715 | EPZ019997|GSK-3368715|GSK 3368715 | GSK3368715 (EPZ019997) inhibits members of the type I PRMT family, which potentially in decreased tumor growth (PMID: 31257072). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | lung non-small cell carcinoma | not applicable | GSK3368715 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK3368715 inhibited growth of non-small cell lung cancer cell lines in culture, and demonstrated cytotoxicity in 17% of cell lines tested (PMID: 31257072). | 31257072 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | GSK3368715 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GSK3368715 inhibited tumor growth in a triple-negative breast cancer cell line xenograft model (PMID: 31257072). | 31257072 |
| Unknown unknown | lymphoma | not applicable | GSK3368715 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK3368715 inhibited growth of lymphoma cell lines in culture, and demonstrated cytotoxicity in 56% of cell lines tested (PMID: 31257072). | 31257072 |
| Unknown unknown | acute myeloid leukemia | not applicable | GSK3368715 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK3368715 inhibited growth of acute myeloid leukemia cell lines in culture, and demonstrated cytotoxicity in 50% of cell lines tested (PMID: 31257072). | 31257072 |
| Unknown unknown | pancreatic adenocarcinoma | not applicable | GSK3368715 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GSK3368715 inhibited growth of a pancreatic adenocarcinoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 31257072). | 31257072 |
| Unknown unknown | diffuse large B-cell lymphoma | not applicable | GSK3368715 | Preclinical - Patient cell culture | Actionable | In a preclinical study, GSK3368715 treatment inhibited growth of a diffuse large B-cell lymphoma (DLBCL) cell line in culture and inhibited tumor growth in xenograft models, and inhibited growth of patient-derived DLBCL cells in culture PMID: 31257072). | 31257072 |
| Unknown unknown | clear cell renal cell carcinoma | not applicable | GSK3368715 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK3368715 inhibited tumor growth in a clear cell renal cell carcinoma xenograft model (PMID: 31257072). | 31257072 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | USA | CAN | 2 |
CKB BOOST